Results 1 to 10 of about 577,779 (292)

Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease [PDF]

Journal of Experimental Pharmacology, 2020
Josuel Ora,1 Angelo Coppola,2 Mario Cazzola,3 Luigino Calzetta,4 Paola Rogliani1,3 1Division of Respiratory Medicine, University Hospital Tor Vergata, Rome, Italy; 2Division of Respiratory Medicine, San Filippo Neri Hospital, Rome, Italy; 3Department of ...
Ora J, Coppola A, Cazzola M, Calzetta L, Rogliani P   +4 more
doaj   +3 more sources

The impact of long-acting muscarinic antagonists on mucus hypersecretion and cough in chronic obstructive pulmonary disease: a systematic review. [PDF]

Eur Respir Rev, 2022
Patients suffering from chronic obstructive pulmonary disease (COPD) clinically manifest airway mucus hypersecretion as sputum expectoration and cough.
Calzetta L, Ritondo BL, Zappa MC, Manzetti GM, Perduno A, Shute J, Rogliani P.   +6 more
europepmc   +2 more sources

Association of Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists With Asthma Control in Patients With Uncontrolled, Persistent Asthma: A Systematic Review and Meta-analysis.

JAMA, 2018
Sobieraj DM, Baker WL, Nguyen E, Weeda ER, Coleman CI, White CM, Lazarus SC, Blake KV, Lang JE.   +8 more
europepmc   +4 more sources

The Impact of Muscarinic Receptor Antagonists on Airway Inflammation: A Systematic Review

International Journal of COPD, 2021
Luigino Calzetta,1 Angelo Coppola,2 Beatrice Ludovica Ritondo,3 Matteo Matino,3 Alfredo Chetta,1 Paola Rogliani2,3 1Department of Medicine and Surgery, Respiratory Disease and Lung Function Unit, University of Parma, Parma, Italy; 2Division of ...
Calzetta L, Coppola A, Ritondo BL, Matino M, Chetta A, Rogliani P   +5 more
doaj   +2 more sources

Inhaled corticosteroids with combination inhaled long-acting beta₂-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease [PDF]

Cochrane Database of Systematic Reviews, 2016
BACKGROUND Management of chronic obstructive pulmonary disease (COPD) commonly involves long-acting bronchodilators including beta-agonists (LABA) and muscarinic antagonists (LAMA).
Amir Soltani, Clinton J White, Julia AE Walters, E. Haydn Walters   +3 more
openalex   +2 more sources

Positioning of Long-Acting Muscarinic Antagonists in the Management of Asthma. [PDF]

Allergy Asthma Immunol Res, 2017
Despite a range of efficacious therapies for asthma, including inhaled corticosteroids (ICS) and long-acting β2-agonists (LABA), a significant proportion of patients have poor asthma control and retain a risk of future worsening of their symptoms.
Aalbers R, Park HS.
europepmc   +2 more sources

Biomarkers to Predict Response to Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists in Adolescents and Adults with Mild Persistent Asthma. [PDF]

Ann Am Thorac Soc, 2022
Krishnan JA, Lazarus SC, Blake KV, Sorkness CA, Covar R, Dyer AM, Lang JE, Lugogo NL, Mauger DT, Wechsler ME, Wenzel SE, Cardet JC, Castro M, Israel E, Phipatanakul W, King TS.   +15 more
europepmc   +3 more sources

The muscarinic antagonists scopolamine and atropine are competitive antagonists at 5-HT3 receptors. [PDF]

Neuropharmacology, 2016
Lochner M, Thompson AJ.
europepmc   +2 more sources

Synthesis, Affinity Profile, and Functional Activity of Muscarinic Antagonists with a 1-Methyl-2-(2,2-alkylaryl-1,3-oxathiolan-5-yl)pyrrolidine Structure

Journal of Medicinal Chemistry, 2007
Starting from a previously studied muscarinic ligand, characterized by a 1,3-oxathiolane nucleus, a new series of muscarinic antagonists were designed by increasing the stereochemical complexity of the molecules.
Silvia Dei, Cristina Bellucci, Michela Buccioni, Marta Ferraroni, Luca Guandalini, Dina Manetti, Elisabetta Martini, Gabriella Marucci, Rosanna Matucci, Marta Nesi, María Novella Romanelli, Serena Scapecchi, Elisabetta Teodori   +12 more
openalex   +2 more sources

Efficacy and Safety of DA-8010, a Novel M3 Antagonist, in Patients With Overactive Bladder: A Randomized, Double-Blind Phase 2 Study [PDF]

International Neurourology Journal, 2022
Purpose DA-8010 is a novel muscarinic M3 receptor antagonist with significant selectivity for bladder over salivary gland in preclinical studies. We evaluated the clinical efficacy and safety of DA-8010 in overactive bladder (OAB) patients.
Hee Seo Son, Cheol Young Oh, Myung-Soo Choo, Hyeong Gon Kim, Joon Chul Kim, Kyu-Sung Lee, Dong Gil Shin, Sung Yong Cho, Seong Jin Jeong, Ju Tae Seo, Hana Yoon, Hong Sang Moon, Jang Hwan Kim   +12 more
doaj   +1 more source